7 reports

SGLT-## inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

SGLT-## inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug analysis: Farxiga

9091 10000 7727

SGLT-## inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.

  • Diabetes
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • European Union
  • Japan
  • United States

Drug Overview: Farxiga

9091 10000 7727

SGLT-## inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Physician Views: As momentum grows for the SGLT-## inhibitor class, can AstraZeneca' s Farxiga move into Invokana' s slipstream?

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Therapy
  • United States

What is the likelihood that availability of Glyxambi will play a significant role in slowing the progression of patients to treatment with a GLP-## agonist?

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Therapy
  • United States

How they would describe the typical patient resistance levels to inter-class brand switching within the DPP-## inhibitor and SGLT-## inhibitor classes?

  • Antidiabetics
  • Insulin
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Therapy
  • United States